TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.

被引：2
|
作者：
Van Cutsem, Eric
Benedetti, Fabio M.
Mizuguchi, Hirokazu
Mayer, Robert J.
Falcone, Alfredo
Garcia-Carbonero, Rocio
Tabernero, Josep
Sobrero, Alberto F.
Peeters, Marc
Zaniboni, Alberto
Yoshino, Takayuki
Shimada, Yasuhiro
Yamazaki, Kentaro
Komatsu, Yoshito
Hochster, Howard S.
Lenz, Heinz-Josef
Ben Tran
Ohtsu, Atsushi
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] Taiho Oncol Inc, Princeton, NJ USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Azienda Osped Univ Pisana, Pisa, Italy
[5] Hosp Univ Virgen del Rocio, Seville, Spain
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] IRCCS AOU San Martino IST, Genoa, Italy
[8] Univ Antwerp Hosp, Edegem, Belgium
[9] Fdn Poliambulanza, Brescia, Italy
[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[11] Natl Canc Ctr, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo, Japan
[12] Saitama Canc Ctr, Saitama, Japan
[13] Hokkaido Univ, Hosp Canc Ctr, Sapporo, Hokkaido, Japan
[14] Yale Canc Ctr, New Haven, CT USA
[15] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[16] Royal Melbourne Hosp, Melbourne, Vic, Australia
[17] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.638
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
638
引用
收藏
页数：1
相关论文
共 50 条
  • [1] TAS-102 vs placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the RECOURSE trial
    Van Cutsem, Eric
    Benedetti, Fabio M.
    Mizuguchi, Hirokazu
    Mayer, Robert J.
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)
    Shinozaki, E.
    Laurent, S.
    Gravalos, C.
    Benavides, M.
    Longo Munoz, F.
    Mizuguchi, H.
    Wahba, M.
    Ychou, M.
    Ciardiello, F.
    Siena, S.
    Yamaguchi, K.
    Muro, K.
    Denda, T.
    Tsuji, Y.
    Loehrer, P.
    Lenz, H. J.
    Tebbutt, N.
    Mayer, R. J.
    Van Cutsem, E.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S383 - S384
  • [3] Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC)
    Yoshino, T.
    Cleary, J.
    Mayer, R.
    Yoshida, K.
    Makris, L.
    Yamashita, F.
    Ohtsu, A.
    Lenz, H-J.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial.
    Cleary, James M.
    Mayer, Robert J.
    Van Cutsem, Eric
    Yamashita, Fumiaki
    Yoshisue, Kunihiro
    Ieiri, Ichiro
    Ohtsu, Atsushi
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC)
    Falcone, A.
    Garcia-Carbonero, R.
    Tabernero, J.
    Sobrero, A.
    Peeters, M.
    Zaniboni, A.
    Hochster, H.
    Lenz, H. J.
    Tran, B.
    Yamaguchi, K.
    Muro, K.
    Denda, T.
    Tsuji, Y.
    Wahba, M.
    Benedetti, F.
    Ohtsu, A.
    Mayer, R. J.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S383 - S383
  • [6] Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer
    Yamazaki, K.
    Yoshino, T.
    Shinozaki, E.
    Komatsu, Y.
    Tsuji, Y.
    Nishina, T.
    Baba, H.
    Denda, T.
    Sugimoto, N.
    Tsuji, A.
    Yamaguchi, K.
    Takayama, T.
    Shimada, Y.
    Hamamoto, Y.
    Muro, K.
    Gotoh, M.
    Tanase, T.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups
    Ohtsu, Atsushi
    Yoshino, Takayuki
    Wahba, Mona M.
    Benedetti, Fabio M.
    Mayer, Robert J.
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup
    Falcone, A.
    Laurent, S.
    Gravalos, C.
    Benavides, M.
    Munoz, F. Longo
    Ychou, M.
    Ciardiello, F.
    Siena, S.
    Yamaguchi, K.
    Muro, K.
    Denda, T.
    Tsuji, Y.
    Tebbutt, N.
    Loehrer, P. J.
    Lenz, H. -J.
    Mayer, R. J.
    Ohtsu, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [9] Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
    Ohtsu, Atsushi
    Yoshino, Takayuki
    Wahba, Mona M.
    Benedetti, Fabio M.
    Falcone, Alfredo
    Garcia-Carbonero, Rocio
    Tabernero, Josep
    Sobrero, Alberto F.
    Peeters, Marc
    Zaniboni, Alberto
    Shimada, Yasuhiro
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Hochster, Howard S.
    Lenz, Heinz-Josef
    Ben Tran
    Mayer, Robert J.
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
    Van Cutsem, Eric
    Mayer, Robert J.
    Laurent, Stephanie
    Winkler, Robert
    Gravalos, Cristina
    Benavides, Manuel
    Longo-Munoz, Federico
    Portales, Fabienne
    Ciardiello, Fortunato
    Siena, Salvatore
    Yamaguchi, Kensei
    Muro, Kei
    Denda, Tadamichi
    Tsuji, Yasushi
    Makris, Lukas
    Loehrer, Patrick
    Lenz, Heinz-Josef
    Ohtsu, Atsushi
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 63 - 72
12345